HT-29 Xenograft Model Service for Colon Cancer

The HT-29 xenograft model is a well-established preclinical platform for colon cancer research, enabling robust evaluation of therapeutic efficacy, tumor growth kinetics, and molecular response mechanisms in vivo. Alfa Cytology provides comprehensive HT-29 xenograft model services tailored to your drug discovery pipeline, delivering reproducible tumor data with integrated histopathological, biomarker, and pharmacodynamic endpoints to accelerate your preclinical decision-making.

Overview of HT-29 Xenograft Model for Colon Cancer

The HT-29 cell line was established in 1964 from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female patient. It forms moderately differentiated adenocarcinoma consistent with the original primary tumor. As a microsatellite-stable (MSS), CpG island methylator phenotype-positive (CIMP+) cell line, HT-29 harbors the pathogenic BRAF V600E mutation alongside TP53 R273H, APC truncating mutations, PIK3CA P449T, and SMAD4 Q311Ter alterations. Notably, HT-29 retains wild-type KRAS status, distinguishing it from other commonly used colorectal cancer cell lines such as SW480 or HCT-116. The cell line exhibits epithelial morphology with glandular features and demonstrates robust tumorigenicity when implanted subcutaneously or orthotopically into immunodeficient mouse strains including athymic nude and NOD/SCID mice.

In xenograft applications, HT-29 tumors typically reach palpable size within 2--4 weeks post-inoculation, displaying consistent growth kinetics and histopathological characteristics. The model has been extensively validated for evaluating standard chemotherapeutic agents including 5-fluorouracil and irinotecan, as well as novel targeted therapies such as BRAF inhibitors, nanoparticle-based drug delivery systems, and radiopharmaceuticals. HT-29's high expression of COX-2, FAP, and integrin-alpha6 further supports its utility in studies investigating tumor microenvironment interactions, angiogenesis, and hypoxia-targeted imaging. Both subcutaneous and orthotopic implantation protocols are well-established, with the orthotopic approach enabling assessment of local invasion and metastatic potential more representative of human disease progression.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting BRAF-mutant colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through BRAF V600E and CIMP+ signaling, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for COX-2 and FAP-related markers.

Figure 1. The antiproliferative effects of lycopene on HT-29 cells. (Ataseven, D, et al., 2023)

Cell Line Information: HT-29

The HT-29 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its MSS/CIMP+ molecular profile, BRAF V600E mutation, and wild-type KRAS status make it unique among available colon cancer cell lines and essential for preclinical research targeting this distinct molecular subtype of colorectal carcinoma.

Our Services

Alfa Cytology offers end-to-end HT-29 xenograft model services engineered for precision preclinical oncology research. From cell line authentication and inoculation to tumor monitoring, endpoint analysis, and comprehensive histopathological reporting, our platform ensures data integrity and reproducibility at every stage. We integrate pharmacokinetic profiling, biomarker quantification, and customized study designs to support your compound's transition from bench to development, all while maintaining strict IACUC-compliant protocols and GLP-ready documentation standards.

Workflow of HT-29 Xenograft Model Construction

The construction of HT-29 xenograft models follows a standardized, multi-step workflow designed to ensure tumor reproducibility, animal welfare compliance, and data validity across all preclinical studies. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Preparation: HT-29 cells are authenticated via STR profiling and confirmed for BRAF V600E mutation status. Cells are maintained in McCoy's 5A medium supplemented with 10% FBS under standard culture conditions, harvested at 70--80% confluence, and resuspended in PBS or PBS/Matrigel mixture at a concentration of 5 x 10^6 cells per 100--200 uL.
2. Animal Selection and Acclimatization: Female athymic nude mice (CD1-Foxn1nu) or NOD/SCID mice aged 6--8 weeks are selected based on study requirements. Animals undergo a minimum 7-day acclimatization period with daily health monitoring before tumor cell inoculation.
3. Subcutaneous or Orthotopic Inoculation: For subcutaneous models, HT-29 cells are injected into the lower right flank using a sterile 25-gauge needle. For orthotopic models, cells are surgically implanted into the cecal wall or rectal submucosa under anesthesia to replicate anatomical tumor microenvironment.
4. Tumor Monitoring and Caliper Measurement: Tumor growth is monitored twice weekly via electronic caliper measurement. Tumor volume is calculated using the formula V = (length x width^2) / 2. Mice are randomized into treatment groups when tumors reach 100--200 mm^3.
5. Treatment Administration and Dosing: Test compounds are administered according to the study protocol (oral gavage, intraperitoneal, or intravenous routes). Vehicle controls and reference standards (e.g., 5-FU or irinotecan) are included for comparative efficacy assessment.
6. Endpoint Analysis and Necropsy: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), biomarker analysis (Western blot, qPCR), and pharmacodynamic profiling. Blood samples are collected for PK/PD correlation.
7. Data Compilation and Reporting: All data including tumor growth curves, body weight changes, tumor inhibition rates, and histopathological findings are compiled into a comprehensive study report with statistical analysis and regulatory-compliant documentation.

Figure 2: Schematic workflow illustrating the derivation and construction of the HT-29 Xenograft Model at Alfa Cytology.

Case Study-HT-29 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established HT-29 cells into immunodeficient mice to evaluate the anti-tumor efficacy of a novel therapeutic candidate. Tumors reached the target volume within the expected 2--4 week window, exhibiting consistent growth kinetics suitable for randomized treatment initiation. The study incorporated multi-dose cohorts, vehicle controls, and a reference arm, with tumor growth inhibition and survival endpoints measured throughout the treatment period. Comprehensive histopathological and biomarker analyses were performed at study termination to elucidate mechanism-of-action and pharmacodynamic response. Detailed quantitative data, including tumor growth curves, body weight trajectories, and histopathological scoring, are available upon request --- please contact our team to discuss specific study parameters and receive the full technical report.

Why Choose Alfa Cytology?

Alfa Cytology delivers scientifically rigorous, IACUC-compliant HT-29 xenograft model services with integrated endpoints and flexible study designs to meet your preclinical development needs.

• Verified Cell Line Integrity: Validated HT-29 cell line with confirmed BRAF V600E mutation status and STR authentication for genetic integrity assurance.
• High Take Rates and Consistency: Standardized tumor growth kinetics with reproducible 2--4 week engraftment timelines across multiple immunodeficient strains.
• Comprehensive Analytical Support: Comprehensive endpoint portfolio including tumor volume monitoring, histopathology (H&E, IHC), biomarker quantification, and PK/PD analysis.
• Tailored Study Designs: Flexible study designs accommodating subcutaneous, orthotopic, and metastatic model configurations with customized dosing regimens.
• Standardized Protocols: GLP-ready documentation and regulatory-compliant data packages to support IND-enabling studies and investor due diligence.
• Dedicated Project Management: Dedicated project management with weekly progress updates and direct scientific consultation throughout the study lifecycle.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated HT-29 xenograft model? Contact us today to discuss your study objectives, receive a customized proposal, and explore how Alfa Cytology's preclinical expertise can accelerate your drug development timeline. Our scientific team is standing by to reach out with a tailored solution that aligns with your research goals and regulatory requirements. Please reach out to us today via our inquiry form or email to learn more about our HT-29 Xenograft Model services.

For research use only. Not intended for any clinical use.